MINNEAPOLIS–(BUSINESS WIRE)–NAMSA®, the world’s only 100% medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, announced today its acquisition of Minneapolis-based American Preclinical Services (APS), a full service preclinical CRO. This purchase follows NAMSA’s acquisition of New York-based Syntactx, a leading clinical research services CRO, in January 2021.
With the addition of APS’s portfolio of services, NAMSA will further enhance its already robust preclinical solutions by providing Sponsors with a broader range of laboratory models and analysis tools, including innovative surgical instrumentation and several state-of-the-art catheterization labs, imaging capabilities and surgical suites. These newly augmented services, delivered within APS’s 130,000 sq. ft. facility, will equip medtech innovators with the capability to perform high-quality safety and performance evaluations for early-stage R&D efforts, as well as an integrated preclinical-to-clinical solution for complex medical device programs.
“APS is excited to join forces with NAMSA, the pioneer and long-standing leader of the medical device testing industry,” commented Michael Conforti, APS President and CEO. “With NAMSA’s trusted biocompatibility and biological safety solutions, coupled with both organization’s preclinical services, Sponsors now have a clear choice when partnering with the CRO industry’s foremost expert in medical device development and preclinical research,” he concluded.
“NAMSA is extremely pleased to add to its global portfolio of preclinical development solutions through the acquisition of APS,” remarked John Gorski, NAMSA President and CEO. “We are excited to enhance the NAMSA client experience, and also offer APS clients further efficiencies throughout the full development continuum. Together, we look forward to advancing patient healthcare by efficiently and safely helping Sponsors deliver innovative, life-saving medical technology throughout the world,” concluded Gorski.
The acquisition of APS’s Minneapolis preclinical laboratory adds to NAMSA’s rapidly growing global footprint with 13 locations throughout APAC, Europe and North America.
The price and terms of the transaction are undisclosed.
Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world’s only 100% medical device-focused, full continuum Contract Research Organization (CRO). Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients’ products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services; NAMSA is the industry’s premier, trusted partner for successful development and commercialization outcomes. Web: namsa.com
About American Preclinical Services
American Preclinical Services (APS) is an AAALAC and ISO17025 accredited, USDA registered and GLP compliant Contract Research Organization (CRO) specializing in medical device and pharmaceutical preclinical research. Conveniently located in the heart of the Minneapolis/St. Paul medical device biotech cluster, the experienced scientific and operational staff at APS delivers high quality, timely service with the understanding that in product development, the only constant is change. By utilizing the APS catalogue of services, which include analytical services, biocompatibility testing, bioskills labs, histopathology services, interventional and surgical research and pharmacology and toxicology services, product development teams are able to develop and conduct a full preclinical research program with one trusted partner.
NAMSA Media Contact:
Global Manager, Marketing Communications
American Preclinical Services Contact:
Senior Director, Business Development